NYSE: DHR · Diagnostics & Research
Danaher (DHR) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Danaher (DHR) at $212.19 a share. The stock last closed at $229.91, which puts the model's fair value 7.7% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Danaher Corporation.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $212.19, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $229.91 is 7.7% above it: Fairly valued, on a high evidence grade.
What's nextNext report on 27 Jan 2027. Options prices imply a move of about 9% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give DHR?
The calibrated range for DHR over 63 trading days is $207.76 to $255.72. It sits around the last close, and its width comes from the volatility that DHR's own options imply (31% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $174.80 to $253.39. In 32% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Danaher Corporation is a diversified global technology and science company. It develops, manufactures and distributes a wide array of professional, medical, industrial and commercial products and services across the world.
Faircurve's model put the fair value of Danaher at $212.19 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $210.57, so the fair value moved +0.8%. The calibrated range over 63 trading days is $207.76 to $255.72. Ranges built this way held the price 60% of the time at this horizon, based on 8,038 past valuations. The model grades the evidence High, a grade that looks at input completeness, comparable companies and their agreement, and the spread of outcomes. It does not say whether the fair value is right.
Danaher scores 40 out of 100 on quality against comparable companies, the model's composite of six factors. Earnings quality scores 64 (FCF / net income 1.32x, peer median 1.02x), balance sheet 53 (Net debt / EBITDA 2.93x, peer median 1.48x), and profitability 23 (ROIC 6.3%, peer median 9.8%). The model compares it with Thermo Fisher Scientific Inc. (TMO), IDEXX Laboratories, Inc. (IDXX), Agilent Technologies, Inc. (A), Waters Corporation (WAT), IQVIA Holdings Inc. (IQV), Mettler-Toledo International Inc. (MTD) and Illumina, Inc. (ILMN).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does DHR report earnings, and how has the stock reacted?
Danaher's next earnings report is scheduled for 27 Jan 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 4.0% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. DHR's 30 day implied volatility works out to about 8.9% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across DHR's last 8 reports, ignoring direction, was 5.5%.
What the options market has priced for a month's move in DHR
How does DHR score on business quality?
Danaher's overall quality score is 40 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 23 | 6.3%ROIC | 9.8% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 64 | 1.32xFCF / net income | 1.02x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 37 | 2.9%Revenue growth, trailing | 5.7% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 31 | 0.6%Net buybacks / market value | 2.2% |
| Balance sheetNet debt to EBITDA and interest coverage. | 53 | 2.93xNet debt / EBITDA | 1.48x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 46 | 1.8 ptsEBITDA margin downside volatility, 5y | 1.5 pts |
How does DHR compare with similar companies?
The companies in diagnostics & research closest to Danaher in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | $691.33 | $687.16 | -0.6% | Fairly valued |
| IDXX IDEXX Laboratories, Inc. | $700.65 | $568.18 | -18.9% | Overvalued |
| A Agilent Technologies, Inc. | $172.92 | $176.09 | +1.8% | Fairly valued |
| WAT Waters Corporation | $453.42 | $337.75 | -25.5% | Overvalued |
| IQV IQVIA Holdings Inc. | $264.73 | $335.69 | +26.8% | Undervalued |
| MTD Mettler-Toledo International Inc. | $1,727.26 | $1,679.36 | -2.8% | Fairly valued |
| ILMN Illumina, Inc. | $198.00 | $172.96 | -12.6% | Fairly valued |
| LH Labcorp Holdings Inc. | $372.46 | $465.68 | +25.0% | Low evidence grade |
What the comparable companies' multiples alone would give for DHR, the peer-implied price, is $187.45 a share on this run. The fair value weighs that against the company's own multiple.
All diagnostics & research stocks ranked by gap to fair value
Danaher at a glance
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world.
- Market value
- $163.9B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Revenue expected, next twelve months
- $28.0B
- Consensus revenue growth, next fiscal year
- +6.9%
- Analysts with estimates
- 13
- Beta to the US market
- 0.47
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. DHR was not among them.
How the fair value is worked out: the model prices Danaher on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for DHR was $210.57. As of 14 Nov 2026 it is $212.19, a change of +0.8%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Danaher's valuation
Is Danaher stock undervalued or overvalued?
On Faircurve's model, DHR reads as Fairly valued as of 14 Nov 2026. The model's fair value is $212.19 a share against a last close of $229.91, a gap of -7.7%.
What is DHR's fair value?
$212.19 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $174.80 to $253.39.
What price range does the model give DHR?
$207.76 to $255.72 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Danaher report earnings next?
The next report is scheduled for 27 Jan 2027. Companies can move their dates.
How much has DHR moved on past earnings reports?
Across its last 8 reports the median two session move was 5.5%, ignoring direction. The largest was -10.9% around the report of 21 Jul 2026.
How confident is the model in this valuation?
The model's evidence grade for DHR is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on DHR
The model holds no idea open on DHR today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on DHR with their outcomes. A free account is enough.